<DOC>
	<DOCNO>NCT01770652</DOCNO>
	<brief_summary>Multi-center , non-randomized , open-label , single-dose , parallel group study determine effect impair renal function PK deferiprone 3-O-glucuronide metabolite follow single oral dose 33mg/kg Ferriprox® .</brief_summary>
	<brief_title>An Open-label , Non-randomized , Parallel Group Study Subjects With Mild , Moderate , Severe , No Renal Impairment</brief_title>
	<detailed_description>Post-marketing study evaluate effect impair renal function pharmacokinetics ( PK ) deferiprone 3-O-glucuronide metabolite safety Ferriprox® subject mild , moderate severe renal impairment compare healthy volunteer .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main All subject : 1 . Adult male female , 18 75 year age ( inclusive ) ; 2 . Body weight ≥ 45 kg ; 3 . Body mass index ( BMI ) range approximately 18.532 kg/m^2 ( inclusive ) ; 4 . Absolute neutrophil count ( ANC ) &gt; 1.5x10^9/L ; Healthy volunteer : 1 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , vital sign , physical examination ) ; 2. eGFR ≥ 90 mL/min/1.73m^2 ; Renally impaired subject : 1 . Considered clinically stable opinion Investigator ; 2 . Subjects mild renal impairment ( eGFR 6089 mL/min/1.73m^E2 ) OR moderate renal impairment ( eGFR 3059 mL/min/1.73m^2 ) OR severe renal impairment ( eGFR 1529 mL/min/1.73m^2 ) . Main 1 . History renal transplant ; 2 . Subjects undergo method dialysis ; 3 . History presence clinically unstable significant respiratory , cardiovascular , pulmonary , hepatic , renal ( except subject assign one renally impaired group ) , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease ; 4 . Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence PK investigational medicinal product ( e.g . cholecystectomy , resection small large intestine , febrile condition , chronic diarrhea , chronic vomiting , endocrine disease , severe infection , acute inflammation , etc . ) ; 5 . Clinically significant abnormality 12lead ECG ( e.g. , QTcF≥430 m male ≥450 ms female ) ; 6 . Evidence liver damage : hepatitis B C ; aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) consider clinically significant Investigator ; 7 . Participation another clinical trial within 28 day prior study drug administration ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Renal Impairment</keyword>
	<keyword>Kidney Impairment</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Ferriprox</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>DFP ( deferiprone )</keyword>
	<keyword>L1</keyword>
</DOC>